|
|
|
By Antony Hitchcock, principal and owner, AGH Bioconsulting | Drug developers might want to consider longer-term approaches to meeting manufacturing and regulatory requirements. |
|
|
|
| When Protocol Amendments Meet RTSM | Article | By Marc Weinberg, MBA, Medrio | Learn why an RTSM solution should be adaptive and flexible, and should help clinical trial teams uncover the best ways to handle protocol amendments. |
|
|
|
| The Catalyst Of Decentralized Clinical Trials: Combining Clinical And Digital | Webinar | MRN - Medical Research Network | Decentralized clinical trials are made up of a multitude of elements, from in home clinical capabilities, logistics, digital platforms, and technology, to global reach and more. This webinar shares important factors to consider to build your DCT ‘molecule’ successfully. |
|
|
|
|
|
.png){kind=logo}
